Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
Andrew M. Evens(Rutgers, The State University of New Jersey), Matthew A. Lunning(University of Nebraska Medical Center), Yong Lin(Fujian Medical University), Madelyn Burkart(Atrium Health Wake Forest Baptist), Kirsten M Boughan(Cleveland Clinic), Christopher R. D’Angelo(Susan Thompson Buffett Foundation), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Tatyana Feldman(Hackensack University Medical Center), Kevin A. David(Rutgers, The State University of New Jersey), Catherine Diefenbach(NYU Langone Health), Suchitra Sundaram(Roswell Park Comprehensive Cancer Center), Emma Rabinovich(University of Illinois Chicago), Adam Zayac(Rutgers, The State University of New Jersey), Jeremy Ramdial(The University of Texas MD Anderson Cancer Center), Vaishalee P. Kenkre(University of Wisconsin–Madison), Parameswaran Venugopal(Rush University Medical Center), Michael C. Churnetski(Emory University), Gaurav Varma(NYU Langone Health), Daniel Rector(Hackensack University Medical Center), Peter Martin(Northwestern University), Seo‐Hyun Kim(Rush University Medical Center), Izidore S. Lossos(University of Miami), Allandria Straker-Edwards(Fox Chase Cancer Center), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Amandeep Godara(University of Utah), Kristie A. Blum(Emory University), Catherine Wei(Rutgers, The State University of New Jersey), Andreas K. Klein(Tufts Medical Center), Alexey V. Danilov(City of Hope), Malvi Savani(University of Minnesota), Amy Sperling(Fred Hutch Cancer Center), Victor M. Orellana‐Noia(University of Virginia), Stephanie Berg(Loyola University Medical Center), Nadia Khan(Fox Chase Cancer Center), Seth Maliske(University of Iowa), Seema Naik(CHRISTUS Transplant Institute), Agrima Mian(Cleveland Clinic), Nishitha Reddy(Vanderbilt University), Ayushi Chauhan(Georgetown University), Narendranath Epperla(University of Utah), Stephen D. Smith(Seattle Cancer Care Alliance), Umar Farooq(Wake Forest University), Scott E. Smith(Loyola University Medical Center), Andrzej Stadnik(Oregon Health & Science University), Albert Ren, Ryan Vaca(Penn State Milton S. Hershey Medical Center), Yun Kyong Choi(New York University), Reem Karmali(Northwestern University), Brad M. Haverkos(University of Colorado Cancer Center), Maryam Sarraf Yazdy(Georgetown University)
Cited by 125
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k